MedTrace Logo

Comparison of Pre-procedure Lignocaine Spray Versus Spray-as-you-go for Topical Airway Anesthesia in Flexible Bronchoscopy

NCT07084623 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-07-24

No results posted yet for this study

Summary

Title: Comparing Two Methods of Topical Anesthesia for Fiberoptic Bronchoscopy

Purpose: To compare the effectiveness of two methods of anesthesia, pre-procedure lignocaine spray (PPL) and spray-as-you-go (SAYG), in reducing discomfort and improving operator comfort during fiberoptic bronchoscopy.

Study Design: Randomized controlled trial Participants: 50 patients undergoing fiberoptic bronchoscopy Interventions: Patients received either PPL or SAYG anesthesia

Outcomes:

* Pain perception
* Cough severity
* Operator comfort
* Procedure duration

Results:

* Both PPL and SAYG methods were effective in reducing pain and discomfort
* No significant differences were observed between the two groups in pain perception, cough scores, or procedure duration
* Operator comfort scores showed a trend favoring PPL, but the difference was not statistically significant

Implications: Both PPL and SAYG methods can be effectively used for fiberoptic bronchoscopy, with potential implications for procedural efficiency and patient outcomes.

Conditions

  • Lignocaine
  • Anesthesia, Local
  • Trachea
  • Airway Disease

Interventions

DRUG

Pre-procedure lignocaine spray (PPL)

Administration of 2 mL of 4% lignocaine spray in the oropharynx before the fiberoptic bronchoscopy procedure, followed by additional 2% lignocaine spray according to body weight (3 mg/kg)

DRUG

Lignocaine Spray (Spray-as-you-go)

Administration of 2% lignocaine spray via oral scope insertion during the fiberoptic bronchoscopy procedure, according to body weight (3 mg/kg), with standard procedural sedation with midazolam and initial 2 mL of 4% lignocaine spray in the oropharynx for gag reflex suppression

Sponsors & Collaborators

  • Sheikh Zayed Federal Postgraduate Medical Institute

    lead OTHER

Principal Investigators

  • Talha Mahmud, PhD · Shaikh Zayed Medical Complex, Federal Postgraduate Medical Institute, Lahore Pakistan.

  • Hira Ishtiaq, MD · Shaikh Zayed Medical Complex, Federal Postgraduate Medical Institute, Lahore Pakistan.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07084623 on ClinicalTrials.gov